Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4

Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis

(2016) Byron J. Hoogwerf et al.   Cardiovascular Diabetology

Glucodynamics of long-acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trial

(2016) L. A. Morrow et al.   DIABETES OBESITY & METABOLISM

Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials

(2016) Henry Ginsberg et al.   DIABETES OBESITY & METABOLISM

Basal insulin peglispro versus insulin glargine in insulin-naïve type 2 diabetes: IMAGINE 2 randomized trial

(2016) M. J. Davies et al.   DIABETES OBESITY & METABOLISM

A randomized clinical trial of basal insulin peglispro vs NPH in insulin-naïve patients with type 2 diabetes: the IMAGINE 6 trial

(2016) G. Grunberger et al.   DIABETES OBESITY & METABOLISM

Randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3

(2016) R. M. Bergenstal et al.   DIABETES OBESITY & METABOLISM

A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1

(2016) S. Garg et al.   DIABETES OBESITY & METABOLISM

Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5

(2015) John B. Buse et al.   DIABETES CARE

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

(2015) R. Ritzel et al.   DIABETES OBESITY & METABOLISM

Performance of an Electronic Diary System for Intensive Insulin Management in Global Diabetes Clinical Trials

(2015) Edward J. Bastyr et al.   Diabetes Technology & Therapeutics

Insulin-independent regulation of hepatic triglyceride synthesis by fatty acids

(2015) Daniel F. Vatner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

(2014) Robert R. Henry et al.   DIABETES CARE

β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment

(2014) Philippe A. Halban et al.   DIABETES CARE

Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects

(2014) Vikram P. Sinha et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Estimation of group means when adjusting for covariates in generalized linear models

(2014) Yongming Qu et al.   PHARMACEUTICAL STATISTICS

Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

(2013) M. C. Moore et al.   DIABETES

Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus

(2013) V. P. Sinha et al.   DIABETES OBESITY & METABOLISM

The Future of Basal Insulin

(2013) Viral N. Shah et al.   Diabetes Technology & Therapeutics

Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes: A randomized, crossover study

(2012) J. Rosenstock et al.   DIABETES CARE

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin-Treated Patients With Type 2 Diabetes

(2012) R. M. Bergenstal et al.   DIABETES CARE

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials

(2012) R. E. Ratner et al.   DIABETES OBESITY & METABOLISM

Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging

(2012) Arian Mashhood et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis

(2011) Ajay Chaudhuri et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

General Multistage Gatekeeping Procedures

(2008) Alex Dmitrienko et al.   BIOMETRICAL JOURNAL

10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes

(2008) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE